Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial by Wasan, Harpreet et al.
www.thelancet.com/oncology   Vol 15   May 2014 631
Articles
Intermittent chemotherapy plus either intermittent or 
continuous cetuximab for fi rst-line treatment of patients 
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Summary
Background Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments. 
However, how best to minimise the time spent taking cytotoxic drugs and whether molecular selection can refi ne this 
further is unknown. The primary aim of this study was to establish how cetuximab might be safely and eff ectively 
added to intermittent chemotherapy.
Methods COIN-B was an open-label, multicentre, randomised, exploratory phase 2 trial done at 30 hospitals in the 
UK and one in Cyprus. We enrolled patients with advanced colorectal cancer who had received no previous chemo-
therapy for metastases. Randomisation was done centrally (by telephone) by the Medical Research Council Clinical 
Trials Unit using minimisation with a random element. Treatment allocation was not masked. Patients were 
assigned (1:1) to intermittent chemotherapy plus intermittent cetuximab or to intermittent chemotherapy plus 
continuous cetuximab. Chemotherapy was FOLFOX (folinic acid and oxaliplatin followed by bolus and infused 
fl uorouracil). Patients in both groups received FOLFOX and weekly cetuximab for 12 weeks, then either had a 
planned interruption (those taking intermittent cetuximab) or planned maintenance by continuing on weekly 
cetuximab (continuous cetuximab). On RECIST progression, FOLFOX plus cetuximab or FOLFOX was recommenced 
for 12 weeks followed by further interruption or maintenance cetuximab, respectively. The primary outcome was 
failure-free survival at 10 months. The primary analysis population consisted of patients who completed 12 weeks of 
treatment without progression, death, or leaving the trial. We tested BRAF and NRAS status retrospectively. The trial 
was registered, ISRCTN38375681.
Findings We registered 401 patients, 226 of whom were enrolled. Results for 169 with KRAS wild-type are reported 
here, 78 (46%) assigned to intermittent cetuximab and 91 (54%) to continuous cetuximab. 64 patients assigned to 
intermittent cetuximab and 66 of those assigned to continuous cetuximab were included in the primary analysis. 
10-month failure-free survival was 50% (lower bound of 95% CI 39) in the intermittent group versus 52% (lower 
bound of 95% CI 41) in the continuous group; median failure-free survival was 12·2 months (95% CI 8·8–15·6) and 
14·3 months (10·7–20·4), respectively. The most common grade 3–4 adverse events were skin rash (21 [27%] of 
77 patients vs 20 [22%] of 92 patients), neutropenia (22 [29%] vs 30 [33%]), diarrhoea (14 [18%] vs 23 [25%]), and 
lethargy (20 [26%] vs 19 [21%]).
Interpretation Cetuximab was safely incorporated in two fi rst-line intermittent chemotherapy strategies. Maintenance 
of biological monotherapy, with less cytotoxic chemotherapy within the fi rst 6 months, in molecularly selected 
patients is promising and should be validated in phase 3 trials.
Funding UK Medical Research Council, Merck KGaA. 
Copyright © Wasan et al. Open Access article distributed under the terms of CC BY.
Introduction
The discovery of predictive biomarkers for advanced 
colorectal cancer and the development of new targeted 
treatments has led to the combination of cytotoxic drugs 
with targeted treatments as the international standard of 
care. However, these combinations have failed to improve 
outcomes in several phase 3 trials.1–4 Toxic eff ects caused 
by drug combinations have also confounded assessments 
of effi  cacy.2,3
Intermittent treatment and maintenance biological 
treatment have been explored in several trials to address 
this shortcoming.3–11 Palliative treatment of cancer 
should address both quantity and quality of life. 
Minimising the time spent taking cytotoxic drugs and 
introducing chemotherapy-free intervals or complete 
treatment holidays (ie, planned interruptions) might 
help to meet both these goals. De-escalation of 
components of treatment for maintenance in patients 
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who have not progressed is increasingly done in 
practice and a clinical benefi t has been shown in a trial 
of capecitabine and bevacizumab maintenance treat-
ment.8 However, the best strategy to use for diff erent 
clinically or molecularly defi ned cohorts has yet to be 
established.
The COIN trial1,6 was designed to assess whether 
intermittent chemotherapy was as eff ective as continuous 
chemotherapy and whether the addition of cetuximab to 
continuous chemotherapy was associated with additional 
benefi t. In the COIN-B trial—done as an adjunct to 
COIN—we sought to establish how cetuximab might be 
safely and eff ectively added to intermittent chemotherapy.
Methods
Study design and participants 
We did this open-label, multicentre, randomised, 
exploratory phase 2 trial at 30 hospitals in the UK and 
one in Cyprus. Eligibility criteria were age 18 years or 
older, colorectal adenocarcinoma, inoperable metastatic 
or locoregional measurable disease according to RECIST 
(version 1.1), no previous chemotherapy for metastases, 
WHO per formance status 0–2, and good organ function 
(baseline require ments were: ≥1·5 × 10⁹ neutrophils per L, 
≥100 × 10⁹ platelets per L,  serum bilirubin ≤1·25 × upper 
limit of normal, serum aminotransferases ≤2·5 × upper 
limit of normal, alkaline phosphatase ≤5 × upper limit of 
normal, and estimated creatinine clearance or measured 
glomerular fi ltration rate ≥50 mL/min). All patients were 
eligible irrespective of their EGFR status; however, 
consent was obtained for tumour sample collection. 
Patients were excluded if they had had any previous 
cancer, uncontrolled medical comorbidity likely to 
interfere with COIN-B treatment or response assessment, 
or known brain metastases.
The trial was designed before KRAS mutations were 
identifi ed as predictors of resistance to EGFR monoclonal 
antibody treatment.12 COIN-B was suspended in May, 
2008, and on restarting (January 2009) it included 
prospective KRAS mutation analysis before ran dom-
isation. From January, 2009, only patients whose tumours 
were KRAS wild-type were eligible. While the trial was 
suspended, the KRAS status of enrolled patients was 
assessed.
The trial protocol is available online. All patients gave 
written informed consent. COIN-B was approved by the 
South West Research ethics committee and the Medicines 
and Healthcare Regulatory Agency in the UK and the 
national Bioethics and the Pharmaceutical Services of 
the Ministry of Health in Cyprus.
Randomisation and masking 
The MRC Clinical Trials Unit did the randomisation by 
telephone, using the method of minimisation with a 
random element. The minimisation factors were hospital, 
WHO performance status, previous adjuvant chemo-
therapy, liver metastases, and peritoneal metastases. 
Patients were randomly assigned (1:1) to inter mittent 
chemotherapy plus intermittent cetuximab or 
intermittent chemotherapy plus continuous cetuximab. 
Treatment allocation was not masked.
Procedures 
For prospective KRAS screening, tumour samples were 
obtained from the hospital of diagnosis. RB pyro-
sequenced KRAS codons 12, 13, and 61 with DNA extracted 
from macrodissected formalin-fi xed paraffi  n-embedded 
sections. RB established the mutational status of BRAF 
(codon 600) and NRAS (codons 12, 13, and 61) retro-
spectively for KRAS wild-type patients who consented to 
future bowel cancer research. The appendix shows details 
of the primers used. We also con structed tumour 
microarrays for immuno histochemical analysis of EGFR. 
The chemotherapy backbone was the UK FOLFOX 
regimen, consisting of an introvenous infusion of 
175 mg l-folinic acid given concurrently with 85 mg/m² 
oxaliplatin over 2 h, followed by a 400 mg/m² intravenous 
bolus of fl uorouracil over 5 min followed by 2400 mg/m² 
fl uorouracil intravenous infusion over 46 h.1 Cetuximab 
was given in an initial intravenous dose of 400 mg/m² 
(fi rst dose and on reintroduction) and subsequently at 
250 mg/m² once a week. Each cycle of FOLFOX included 
two doses of cetuximab on days 1 and 8. When cetuximab 
was given in combination with chemotherapy (day 1), 
cetuximab was given fi rst (see protocol for full details of 
the treatment regimens).
Patients in both groups received treatment for 
12 weeks and those with stable or responding disease 
started a chemotherapy-free interval (ie, no FOLFOX). 
Patients assigned to the intermittent cetuximab group 
also ceased treatment with cetuximab, whereas patients 
assigned to continuous cetuximab had planned 
maintenance with continuous cetuximab monotherapy. 
In this period, patients had clinical assessments every 
6 weeks and CT scans every 12 weeks. On RECIST 
For the study protocol see 
http://www.ctu.mrc.ac.uk/
plugins/StudyDisplay/protocols/
COIN-B%20Combined%20
Protocol%20with%20CRFs.pdf
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Figure 1: Trial design
Treatment cycles continued until progressive disease (PD) with maximally tolerated treatment, or patient choice. 
FOLFOX=folinic acid and oxaliplatin followed by bolus and infused fl uorouracil.
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confi rmation of progressive disease, maximum tolerated 
treatment was restarted for a further 12 weeks (fi gure 1). 
The cycling of treatment and complete breaks or 
maintenance could be continued until progressive 
disease on maximally tolerated treatment or patient 
choice. The appendix provides details of permitted dose 
delays and modifi cations. If a patient had a grade 3 or 4 
allergic reaction to cetuximab at any time cetuximab 
was discontinued.
Symptoms were scored with the National Cancer 
Institute Common Toxicity Criteria for Adverse Events 
(version 3.0). Serious adverse events and deaths—together 
with an assessment of causality—were con tinuously 
reported; and were reassessed by an experienced 
oncologist (fi rst by AM, then the trial management group) 
on behalf of the Medical Research Council.
A baseline CT scan was done within 4 weeks before the 
start of treatment and then at least once every 12 weeks 
and evaluated with RECIST criteria. We did not confi rm 
responses with repeat scans nor did we do central 
radiological review. Data were collected via remote data 
capture, except for reports of serious adverse events, 
which were submitted by fax.
Outcomes  
The primary outcome was failure-free survival at 
10 months. A failure was defi ned as stopping maximum 
tolerated treatment as a result of progression or death 
(from any cause). The primary analysis population 
included patients who completed 12 weeks of COIN-B 
treatment (induction phase) without pro gression, death, 
or leaving the trial. Secondary objectives were: safety 
assessment of cetuximab reintroduction, overall survival, 
progression-free survival, response rates, toxic eff ects, 
disease control at 24 weeks (complete response, 
progressive disease, and stable disease), and quality of life.
Time from randomisation (week 0) was used for the 
analysis of failure-free survival and overall survival. 
Progression-free survival was analysed from 12 weeks 
(when the treatment plans of the two groups diverge). At 
the time of analysis, survivors were censored at the date 
they were last known to be alive.
The primary and main secondary outcomes (overall 
survival and progression-free survival in the interval) 
were retrospectively analysed for patients who were triple 
wild-type (for KRAS, BRAF, and NRAS). We also analysed 
biomarker status as a potential prognostic factor for 
failure-free survival and overall survival.
Statistical analysis 
In the MRC FOCUS trial,13 failure-free survival at 
9 months was roughly 50% for patients treated with 
continuous oxaliplatin and infused fl uorouracil chemo-
therapy, while median overall survival was 15·4 months 
with FOLFOX. Data from phase 2 studies14 suggested 
that 50% failure-free survival at 10 months would be a 
suitable primary outcome for the addition of cetuximab.
We designed COIN-B as two separately powered phase 2 
trials, using A’Hern’s single-stage design15 to distinguish 
between a 10-month failure-free survival of 50% (implying 
that the treatment would be worth pursuing in a phase 3 
trial, feasibility and toxic eff ects permitting) and of 35% 
(implying that the treatment would not be worth pursuing). 
The trial was not powered for comparison between the 
treatment groups. The original design aimed to recruit 
136 patients (irrespective of KRAS status, 68 per group) 
with a one-sided α of 5% and 80% power. During the trial’s 
62 KRAS wild-type
 25 assigned to intermittent cetuximab
 37 assigned to continuous cetuximab
107 KRAS wild-type
169 eligible and randomly assigned 
119 patients registered before protocol 
 amendment
 59 assigned to intermittent cetuximab 
 60 assigned to continuous cetuximab
282 patients registered after protocol 
 amendment
57 excluded
 18 no tumour block or analysis 
  failed 
 39 KRAS mutations
175 excluded
 133 had KRAS mutation
 9 had abnormal laboratory
  test results
 1 scan out of date
 1 performance status >2
 1 previous oxaliplatin
 1 resectable metastases
 1 unusual histology
 9 KRAS analysis failed
 7 too ill
 2 died
 9 withdrew consent
 1 chemoradiation within 
  1 month 
78 assigned to intermittent cetuximab 91 assigned to continuous cituximab 
14 did not complete initial 12 weeks 
 of chemotherapy and cetuximab
25 did not complete initial 12 weeks 
 of chemotherapy and cetuximab
64 included in primary analysis 66 included in primary analysis
20 did not restart trial study 
 treatment after first 
 chemotherapy-free interval
 9 early progression or death
 4 patient or doctor choice
 3 complete response or liver 
  surgery
 2 toxic effects
 1 intercurrent illness
 1 lost to follow-up and censored
33 did not restart trial study 
 treatment after first 
 chemotherapy-free interval
  5 early progression or death
 15 patient or doctor choice
  5 complete response or liver 
   surgery
  4 toxic effects
  2 intercurrent illness
  2 lost to follow-up and censored
44 restarted study treatment after first 
 chemotherapy-free interval
33 restarted study treatment after first 
 chemotherapy-free interval
Figure 2: Trial profi le
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suspension, interim data from COIN and COIN-B 
suggested that attrition before 12 weeks was 16% because 
of toxic eff ects or absence of benefi t. As a result, we 
changed the target enrolment so that 158 patients with 
KRAS wild-type would be included, of whom we expected 
136 to be assessable for the primary outcome.
We used the Kaplan-Meier method to assess failure-
free survival, overall survival, and progression-free 
survival. We used Stata (version 11.1) for all statistical 
analyses.
The trial is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN38375681.
Role of the funding source 
The MRC was the overall sponsor of the trial. Staff  from 
the MRC Clinical Trials Unit (who are employees of the 
MRC) were involved in the trial design and were 
responsible for all data collection, management, and 
analysis. Merck KGaA reviewed the report. The writing 
of the report and the decision to submit for publication 
was the responsibility of the COIN-B trial management 
group. The corresponding author had full access to the 
data and had fi nal responsibility for the decision to 
submit for publication.
Results  
Between July 13, 2007, and March 6, 2010, 401 patients 
were registered and 226 patients were enrolled. 169 were 
KRAS wild-type. 78 KRAS wild-type patients were 
assigned to the intermittent cetuximab group and 91 to 
the continuous cetuximab group. More patients in the 
continuous cetuximab group were KRAS wild-type when 
tested retrospectively (fi gure 2). The two groups had 
some diff erences in baseline characteristics associated 
with poor prognosis (table 1). The continuous cetuximab 
group had more elderly patients (age >75 years), more 
with a WHO performance score of 2, more with BRAF 
mutations, and more with primary colon cancers (vs 
rectal) than did the intermittent cetuximab group 
(tables 1, 2).
24 patients had BRAF mutations and 15 had NRAS 
mutations (table 2). 111 (66%) of 169 patients had wild-
type KRAS, BRAF, and NRAS (table 2). When the trial 
started, EGFR expression was the most plausible 
biomarker for cetuximab-related benefi t. It has not since 
been validated and our analysis confi rms that it is not 
informative (data not shown).
At the time of analysis (April 24, 2012), median duration 
of follow-up in the KRAS wild-type intention-to-treat 
population was 32·8 months (IQR 22·9–45·8) in the 
intermittent cetuximab group and 34·2 months (IQR 
27·3–50·4 months) in continuous cetuximab group.
Seven patients did not start protocol treatment: two in 
the intermittent cetuximab group and fi ve in the 
continuous cetuximab group. Two patients were found to 
be ineligible after randomisation (one in each group) and 
fi ve patients died before treatment was initiated (one in 
KRAS wild-type patients All randomised patients
Intermittent 
cetuximab 
(n=78)
Continuous 
cetuximab 
(n=91)
Intermittent 
cetuximab 
(n=112)
Continuous 
cetuximab 
(n=114)
Sex
Men 48 (62%) 55 (60%) 66 (59%) 65 (57%)
Women 30 (38%) 36 (40%) 46 (41%) 49 (43%)
Median age at randomisation (IQR; years) 63 (56–70) 64 (54–71) 64 (57–70) 65 (56–71)
Age >75 years 5 (6%) 12 (13%) 9 (8%) 15 (13%)
WHO performance status
0 38 (49%) 40 (44%) 54 (48%) 53 (46%)
1 35 (45%) 42 (46%) 50 (45%) 51 (45%)
2 5 (6%) 9 (10%) 8 (7%) 10 (9%)
Site of primary tumour
Right or transverse colon 23 (29%) 29 (32%) 32 (29%) 37 (32%)
Left colon or RSJ 30 (38%) 45 (49%) 40 (36%) 56 (49%)
Rectum 25 (32%) 17 (19%) 40 (36%) 21 (18%)
Status of primary tumour
Resected 41 (53%) 48 (53%) 58 (52%) 57 (50%)
Unresected 34 (44%) 41 (45%) 50 (45%) 55 (48%)
Local recurrence 3 (4%) 2 (2%) 4 (4%) 2 (2%)
Distribution of metastases
Liver only 16 (21%) 17 (19%) 21 (19%) 24 (21%)
Liver and elsewhere 39 (50%) 43 (47%) 58 (52%) 55 (48%)
Non-liver 22 (28%) 30 (33%) 32 (29%) 34 (30%)
Data missing[A: Ok?] 1 (1%) 1 (1%) 1 (1%) 1 (1%)
Number of metastatic sites
None 1 (1%) 1 (1%) 1 (1%) 1 (1%)
One 28 (36%) 31 (34%) 39 (35%) 41 (36%)
Two 22 (28%) 35 (38%) 37 (33%) 47 (41%)
Three 27 (35%) 24 (26%) 35 (31%) 25 (22%)
Adjuvant chemotherapy
No 62 (79%) 73 (80%) 90 (80%) 92 (81%)
1–6 months ago 4 (5%) 2 (2%) 5 (4%) 4 (4%)
>6 months ago 12 (15%) 16 (18%) 17 (15%) 18 (16%)
Data are n (%) unless stated otherwise. RSJ= rectosigmoid junction. 
Table 1: Baseline characteristics
Intermittent 
cetuximab 
(n=78)
Continuous 
cetuximab 
(n=91)
All wild-type 53 (68%) 58 (64%)
NRAS mutation 7 (9%) 8 (9%)
BRAF mutation 8 (10%) 16 (18%)
NRAS inconclusive, BRAF wild-type 1 (1%) 1 (1%)
NRAS wild-type, BRAF inconclusive 0 (0%) 1 (1%)
Both inconclusive 0 (0%) 1 (1%)
Mutation analysis not possible* 9 (12%) 6 (6%)
 Data are n (%). KRAS wild-type population only. *Lack of appropriate consent or 
lack of sample. 
 Table 2: Genetics of participants
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the intermittent cetuximab group vs four in the 
continuous cetuximab group). 13 patients (fi ve vs eight) 
received capecitabine during treatment. Total dose of 
trial drug and dose intensity within the fi rst 12 weeks was 
much the same in each group (data not shown). Most 
patients required a treatment delay, 68 (87%) of 
78 patients in the intermittent cetuximab group and 
74 (81%) of 91 in the continuous cetuximab group. Dose 
modifi cations occurred in similar proportions in each 
group; for cetuximab, modifi cations were made for 
57 (73%) of 78 patients taking intermittent cetuximab 
versus 70 (77%) of 91 taking continuous cetuximab, 
oxaliplatin was modifi ed for 40 (51%) versus 43 (47%) 
patients, and fl uorouracil was modifi ed for 49 (63%) 
versus 51 (56%). Treatment was discontinued because of 
drug-related toxic eff ects for nine (12%) of 78 patients in 
the intermittent group versus 11 (12%) of 91 in the 
continuous group.
The primary analysis included 64 patients in the 
intermittent cetuximab group and 66 in the continuous 
cetuximab group. Patients were excluded for progressive 
disease (one in the intermittent cetuximab group vs four 
in the continuous cetuximab group), death (four vs 14), 
and failure of treatment in the fi rst 12 weeks (nine vs 
seven). The greater dropout from the continuous 
cetuximab group could be a result of diff erences in 
baseline characteristics combined with the greater 
proportion of patients with a BRAF mutation (table 1, 
appendix). In the primary analysis population, at least 
50% of patients were failure-free at 10 months in both 
groups: 32 (50%) of 64 in the intermittent cetuximab 
group and 34 (52%) of 66 in the continuous cetuximab 
group. The lower bound of the 95% CI was 39% and 41%, 
respectively; therefore both groups also exceeded the pre-
defi ned 35% futility limit. Median failure-free survival 
was 12·2 months (95% CI 8·8–15·6) in the intermittent 
cetuximab group and 14·3 months (10·7–20·4) in the 
continuous cetuximab group (fi gure 3A). In an intention-
to-treat analysis (n=169), median failure-free survival was 
12·1 months (95% CI 7·8–14·7) versus 12·0 months 
(8·7–14·5; appendix). Median failure-free survival was 
greater for patients with all wild-type alleles than for 
those with KRAS wild-type only in both treatment 
groups, in both the primary analysis cohort and the 
intention-to-treat population (fi gure 3B; appendix).
In the primary analysis cohort, median overall survival 
was 16·8 months (95% CI 14·5–22·6) in the intermittent 
cetuximab group versus 22·2 months (18·4–28·9) in the 
continuous cetuximab group (fi gure 4A). The diff erence 
in median overall survival was smaller in the intention-
to-treat population (16·0 months, 95% CI 13·3–20·4 vs 
17·5 months, 13·7–21·7; appendix). Median overall 
survival was greater for patients with all wild-type alleles 
than for those with KRAS wild-type only in both 
treatment groups in both the primary analysis cohort and 
the intention-to-treat population (fi gure 4B; appendix).
In the primary analysis cohort, median progression-
free survival from week 12 was 3·1 months 
(95% CI 2·8–4·7) in the intermittent cetuximab group 
and 5·8 months (4·9–8·6) with continuous cetuximab 
(fi gure 5A). As with the other survival endpoints, median 
progression-free survival was greater for patients with all 
wild-type alleles than for those with KRAS wild-type, for 
both treatment groups (fi gure 5B).
54 (32%) of 78 patients died in the intermittent 
cetuximab group versus 67 (40%) of 91 in the continuous 
cetuximab group. 112 (93%) deaths were caused by 
colorectal cancer (49 vs 63), three (2%) were related to 
treatment (one vs two), and six (5%) were the result of 
other causes (four vs two).
Only 77 patients restarted trial treatment after a 
chemotherapy-free interval, 44 taking intermittent 
cetuximab and 33 taking continuous cetuximab. Median 
chemotherapy-free interval was 3·7 months (95% CI 
3·5–4·6) versus 5·5 months (3·4–7·5; p=0·042; fi gure 2, 
appendix).
Patients in both groups received the same treatment 
for the fi rst 12 weeks, yet a greater proportion of patients 
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Figure 3: Kaplan-Meier analyses of failure-free survival
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in the intermittent cetuximab group had a complete or 
partial response (49 of 78 [63%, 95% CI 51–74]) than did 
those receiving continuous cetuximab (39 of 91 [43%, 
95% CI 33–54]). This fi nding is probably a result of 
imbalances in patients’ baseline characteristics. For 
patients who survived at least 24 weeks, greater disease 
control (ie, complete response, partial response, or 
stable disease) was noted in those assigned to continuous 
cetuximab (n=29, 32%) than in those assigned to 
intermittent cetuximab (n=17, 22%), despite the 
imbalances.
Patients with mutations in KRAS, NRAS, and BRAF had 
a worse prognosis than patients with wild-type for overall 
survival and failure-free survival in the intention-to-treat 
population (p<0·0001 for both outcomes; appendix).
Toxic eff ects and adverse events were similar in each 
treatment group. The most common grade 3–4 adverse 
events were skin rash (21 [27%] of 77 in the intermittent 
cetuximab group vs 20 [22%] of 92 in the continuous 
cetuximab group, neutropenia (22 [29%] vs 30 [33%]), 
diarrhoea (14 [18%] vs 23 [25%]), and lethargy (20 [26%] vs 
19 [21%]). Three patients in the intermittent cetuximab 
group reported grade 3 or higher hyper sensitivity events 
with only one on reintroduction of cetuximab (table 3).
Both the COIN and COIN-B trials contained a quality-of-
life substudy. Patient and carer participation was optional 
and compliance in COIN-B was low, with 42 patients and 
23 carers consenting to participate. Results from these 
substudies will be presented separately.
Discussion
Our fi ndings show that cetuximab can be safely and 
eff ectively incorporated in two intermittent chemo-
therapy strategies, where the cytotoxic doublet induction 
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chemo therapy is given for only 3 months. Although not 
statistically compared, maintenance cetuximab with 
inter mittent chemotherapy seemed to be slightly more 
active than intermittent cetuximab with intermittent 
chemotherapy.
COIN-B is one of a series of trials of patients with non-
curable advanced colorectal cancer to explore strategies 
to improve the combinations and sequences of cytotoxic 
chemotherapy, newer targeted treatments, planned 
maintenance, and planned interruptions; all with a focus 
on reducing toxic eff ects and improving quality of life 
without reducing survival. The emergence of clinical and 
molecular biomarkers—both prognostic and predictive—
has enabled these strategies to be further refi ned. In 
some trials, part or all of the fi rst-line chemotherapy is 
discontinued in the investigational group and compared 
with continuation of the full fi rst-line treatment.4,7,11,16 In 
others, planned maintenance is compared with a planned 
interruption5,8,9 or an additional maintenance treatment 
is introduced when chemotherapy is discontinued.10 In 
all these studies, the conventional surrogate endpoint of 
progression-free survival is inappropriate because it does 
not consider the subsequent benefi t of planned 
reintroduction of full fi rst-line treatment on progression. 
Other outcome measures have therefore been used 
(duration of disease control and failure-free survival).5 
However, the best measure of how maintenance 
treatment aff ects the course of disease is progression-
free survival in the interval.
The COIN trial adds to preliminary data from CR06 
and OPTIMOX-1,11,16 which suggested that interruption or 
de-escalation of treatment was safe and potentially 
benefi cial. The results of Adams and colleagues6 could 
not exclude the possibility of a very small negative eff ect 
on overall survival of a treatment holiday after 3 months 
of cytotoxic chemotherapy. The upper limits of the two-
sided 80% CIs for the hazard ratios (HRs) in both the 
per-protocol and intention-to-treat analyses were greater 
than the predefi ned non-inferiority boundary of 1·162. 
The HR in the intention-to-treat population (n=1630) was 
1·084 (80% CI 1·008–1·165) and in the per-protocol 
population (n=978) it was 1·087 (0·986–1·198).6 Planned 
subgroup analyses showed that patients with normal 
baseline platelet counts could gain the benefi ts of 
intermittent chemotherapy without harming survival. 
This fi nding suggests that a planned interruption might 
not be detrimental to most patients and warrants further 
study with clinical or molecular predictive markers.
COIN-B was designed as an exploratory, hypothesis-
generating study to complement COIN. At random-
isation, only infusional fl uorouracil in com bination with 
oxaliplatin and cetuximab was allowed, which removed 
the confounding eff ect and possible negative interaction 
reported in COIN and other studies when capecitabine 
was the partner fl uoropyrimidine.17 In COIN-B, planned 
maintenance with cetuximab (ie, continuous cetuximab) 
was associated with a greater failure-free survival, greater 
progression-free survival, greater overall survival, 
improved disease control at 24 weeks, and a longer 
chemotherapy-free interval than was intermittent 
cetuximab. These benefi ts occurred despite an imbalance 
of prognostic factors at baseline. Such an imbalance 
might be considered a limitation of a small study such as 
COIN-B; however, the main reason for the imbalance 
between groups was discovered after the change in the 
population of interest from all patients with advanced 
Intermittent cetuximab (n=78) Continuous cetuximab (n=91)
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Nausea 17 (22%) 39 (50%) 16 (21%) 6 (8%) 0 (0%) 37 (41%) 32 (35%) 18 (20%) 4 (4%) 0 (0%)
Vomiting 37 (47%) 19 (24%) 13 (17%) 8 (10%) 1 (1%) 58 (64%) 1618%) 12 (13%) 5 (5%) 0 (0%)
Anorexia 22 (28%) 24 (31%) 26 (33%) 6 (8%) 0 (0%) 31 (34%) 32 (35%) 25 (27%) 3 (3%) 0 (0%)
Pain 13 (17%) 29 (37%) 21 (27%) 12 (15%) 3 (4%) 21 (23%) 21 (23%) 32 (35%) 16 (18%) 1 (1%)
Stomatitis 14 (18%) 26 (33%) 29 (37%) 9 (12%) 0 (0%) 22 (24%) 28 (31%) 35 (38%) 6 (7%) 0 (0%)
Diarrhoea 16 (21%) 24 (31%) 24 (31%) 14 (18%) 0 (0%) 17 (19%) 32 (35%) 19 (21%) 22 (24%) 1 (1%)
Lethargy 7 (9%) 20 (26%) 31 (40%) 18 (23%) 2 (3%) 15 (16%) 24 (26%) 33 (36%) 18 (20%) 1 (1%)
Thrombocytopenia 37 (47%) 35 (45%) 4 (5%) 2 (3%) 0 (0%) 49 (54%) 28 (31%) 11 (12%) 2 (2%) 1 (1%)
Abnormal haemoglobin concentration 17 (22%) 28 (36%) 28 (36%) 3 (4%) 2 (3%) 28 (31%) 36 (40%) 23 (25%) 3 (3%) 1 (1%)
Leucopenia 37 (47%) 17 (22%) 15 (19%) 8 (10%) 1 (1%) 45 (49%) 16 (18%) 18 (20%) 11 (12%) 1 (1%)
Neutropenia 32 (41%) 13 (17%) 11 (14%) 16 (21%) 6 (8%) 40 (44%) 10 (11%) 11 (12%) 22 (24%) 8 (9%)
Skin rash 6 (8%) 18 (23%) 33 (42%) 21 (27%) 0 (0%) 12 (13%) 18 (20%) 41 (45%) 20 (22%) 0 (0%)
Hand-foot syndrome 26 (33%) 25 (32%) 21 (27%) 6 (8%) 0 (0%) 30 (33%) 21 (23%) 33 (36%) 7 (8%) 0 (0%)
Peripheral neurotoxicity 12 (15%) 41 (53%) 21 (27%) 4 (5%) 0 (0%) 18 (20%) 52 (57%) 17 (19%) 4 (4%) 0 (0%)
Hypomagnesaemia 44 (56%) 25 (32%) 6 (8%) 1 (1%) 2 (3%) 44 (48%) 35 (38%) 6 (7%) 4 (4%) 2 (2%)
Cetuximab hypersensitivity 70 (90%) 4 (5%) 1 (1%) 3 (4%) 0 (0%) 76 (84%) 9 (10%) 6 (7%) 0 (0%) 0 (0%)
Data are n (%). For KRAS wild-type patients. 
Table 3: Toxic eff ects
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colorectal cancer to those who had KRAS wild-type 
tumours. 119 patients were enrolled before the 
introduction of KRAS screening, 62 of whom were 
subsequently found to be KRAS wild-type and included 
in the primary outcome analysis. Of these 62, 25 had 
been previously assigned to the intermittent group and 
37 had been assigned to continuous cetuximab. When 
prospective KRAS screening was introduced, 107 patients 
were randomly assigned: 52 to intermittent cetuximab 
and 55 to continuous cetuximab. Furthermore, the 
benefi ts of planned maintenance were even greater in 
patients who were triple wild-type (KRAS, NRAS, and 
BRAF). This fi nding is consistent with data for EGFR 
inhibitors as fi rst-line treatment.18,19
Other studies comparing planned maintenance 
treatment with planned interruption have shown 
evidence of a benefi t of maintenance treatment. In 
OPTIMOX-2, planned maintenance with infusions of 
fl uorouracil and leucovorin prolonged disease control 
compared with a planned interruption although it had no 
signifi cant eff ect on overall survival (23·8 months vs 
19·5 months, HR 0·85; p=0·42).5 In CAIRO-3,8 planned 
maintenance with bevacizumab and capecitabine was 
compared with a planned interruption, after 4 months of 
induction treatment with capecitabine, oxaliplatin, and 
bevacizumab. Planned maintenance improved pro-
gression-free survival in the interval (4·1 months vs 
8·5 months, HR 0·44, 95% CI 0·37–0·54; p<0·0001) and 
overall survival (17·9 months vs 21·7 months, HR 0·77, 
95% CI 0·62–0·96; p=0·02). In the SAKK study,9 non-
inferiority of a planned interruption of all treatment 
compared with maintenance bevacizumab could not be 
shown. Median time to progression was 17·9 weeks (95% 
CI 13·3–23·4) for bevacizumab continuation and 12·6 
weeks (12·0–16·4) for no continuation (HR 0·72, 95% CI 
0·56–0·92). COIN-B is the fi rst trial to enrol patients 
with KRAS wild-type to diff erent intermittent treatment 
schedules and therefore show the eff ect of planned 
maintentance with a targeted monotherapy in a 
molecularly selected subgroup.
Two other studies have tested EGFR inhibition as 
planned maintenance treatment. The DREAM study10 
compared bevacizumab alone or combined with erlotinib 
after 4–6 months of induction with bevacizumab-based 
chemotherapy. Progression-free survival in the interval 
was improved from 4·8 months with bevacizumab alone 
to 5·9 months with bevacizumab and erlotinib (HR 0·76, 
95% CI 0·61–0·94; p=0·01). No diff erence in overall 
survival was recorded. No molecular selection criteria were 
applied to the randomly assigned cohort, which remains a 
serious limitation to bevacizumab monotherapy as a 
maintenance strategy for colorectal cancer. Thus, the best 
strategies by which to integrate bevacizumab and 
cetuximab into treatment are diff erent, because no pre-
dictive biomarker has been discovered for bevacizumab.
The NORDIC-VII trial4 investigated the effi  cacy of 
cetuximab when added to bolus fl uorouracil with folinic 
acid and oxaliplatin (Nordic FLOX) in patients with 
previously untreated metastatic colorectal cancer. Patients 
were randomly assigned to receive standard Nordic 
FLOX, cetuximab and Nordic FLOX, or cetuximab 
combined with intermittent Nordic FLOX. KRAS status 
was assessed retrospectively. Overall survival was almost 
identical in all three groups (20·4 months vs 19·7 months 
vs 20·3 months). The investigators did not compare 
planned maintenance with cetuximab with a planned 
interruption and had no mandated criteria for 
chemotherapy reintroduction; however, the similarity in 
overall survival between groups suggests that main-
tenance cetuximab might be an alternative strategy to 
continuing chemotherapy until progression.
The life expectancy of patients with advanced colorectal 
cancer is increasing, raising questions of duration and 
intensity of treatment required. Initial induction treatment 
followed by de-escalation of cytotoxic drugs and planned 
maintenance treatment is gaining credence, similar to 
treatment strategies for acute myeloid leukaemia. For 
EGFR inhibitors, greater refi nement of biomarker 
selection suggests maintenance monotherapy might be a 
favourable continuation strategy (panel).
The molecular evolution of panitumumab resistance 
has been elegantly shown in patients who were initially 
diagnosed as KRAS wild-type but soon developed 
detectable mutations in KRAS in their sera (three of 
whom developed several diff erent KRAS mutations).21 
The appearance of these mutations consistently occurred 
5–6 months after the start of treatment, which coincides 
with the clinical benefi t noted with EGFR inhibitors used 
Panel: Research in context
Systematic review
At the time of study inception, very few randomised trials 
had been done of cetuximab and chemotherapy, all of which 
were reviewed to help power the study, and choose the 
outcome measures. Stopping and restarting cetuximab could 
in theory increase the risk of hypersensitivity, so establishing 
safety was a main aim. We designed COIN-B to complement 
the COIN trial.1,6 COIN fi rst tested the non-inferiority of 
intermittent chemotherapy compared with continuous 
chemotherapy and second, the addition of cetuximab to 
continuous chemotherapy for superiority. No systematic 
review of the scientifi c literature was done. 
Interpretation
In this trial, cetuximab was safely incorporated in two novel 
intermittent chemotherapy strategies. Continuous cetuximab 
(as planned maintenance monotherapy) was associated with 
a higher failure-free survival, longer chemotherapy-free 
interval, and longer time to progression. This fi nding needs to 
be validated in phase 3 trials, such as the upcoming FOCUS 4 
study,20 in which novel targeted treatments will be assessed in 
biomarker-enriched populations.
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as monotherapy. This could explain why solid tumours 
develop resistance to targeted treatments in a highly 
stereotypical fashion. The hypothesis that minimal 
residual disease in cancer is controlled, but rarely 
eradicated, implies that on–off  strategies with drugs 
might be a rational way to regulate clonal selection 
favourably in palliative care. Our fi ndings show that 
targeted treatment in a molecularly selected subgroup 
seems to improve outcomes and might delay the onset of 
clinical resistance. Other studies concur with COIN-B 
with respect to the benefi t of planned maintenance, 
although both the best duration of induction 
chemotherapy and the benefi t of continuing maintenance 
cytotoxic drugs to achieve maximal clinical benefi t, are 
unknown. Further clinical trials are warranted to 
investigate these points.
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